Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 14/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 14/20 | 0.61 |
| ▸ | PARP1 | P09874 | 11/20 | 0.61 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508380 | 0.83 | TNKS2 (0.56) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL4499752 | 0.79 | TNKS (0.60) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL17711052 | 0.77 | KDM4C (0.57) | TNKSTNKS2PARP1 | |
| SCHEMBL15775476 | 0.76 | TNKS (1.00) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL15775325 | 0.72 | TNKS (1.00) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL20665832 | 0.72 | TNKS (0.66) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL17829611 | 0.71 | TNKS (0.72) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL1387263 | 0.71 | PARP1 (1.00) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL15775474 | 0.70 | TNKS (1.00) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL15775949 | 0.70 | TNKS (1.00) | TNKSTNKS2PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | claimed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | TNKS 116/4885TNKS2 78/4885PARP1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.